Biodistribution of the 18F-FPPRGD2 PET radiopharmaceutical in cancer patients: an atlas of SUV measurements

Ryogo Minamimoto, Mehran Jamali, Amir Barkhodari, Camila Mosci, Erik Mittra, Bin Shen, Frederick Chin, Sanjiv Sam Gambhir, Andrei Iagaru

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose: The aim of this study was to investigate the biodistribution of 2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid (RGD) peptide (PEG3-E[c{RGDyk}]2) (18F-FPPRGD2) in cancer patients and to compare its uptake in malignant lesions with 18F-FDG uptake. Methods: A total of 35 patients (11 men, 24 women, mean age 52.1 ± 10.8 years) were enrolled prospectively and had 18F-FPPRGD2 PET/CT prior to treatment. Maximum standardized uptake values (SUVmax) and mean SUV (SUVmean) were measured in 23 normal tissues in each patient, as well as in known or suspected cancer lesions. Differences between 18F-FPPRGD2 uptake and 18F-FDG uptake were also evaluated in 28 of the 35 patients. Results: Areas of high 18F-FPPRGD2 accumulation (SUVmax range 8.9 – 94.4, SUVmean range 7.1 – 64.4) included the bladder and kidneys. Moderate uptake (SUVmax range 2.1 – 6.3, SUVmean range 1.1 – 4.5) was found in the choroid plexus, salivary glands, thyroid, liver, spleen, pancreas, small bowel and skeleton. Compared with 18F-FDG, 18F-FPPRGD2 showed higher tumor-to-background ratio in brain lesions (13.4 ± 8.5 vs. 1.1 ± 0.5, P < 0.001), but no significant difference in body lesions (3.2 ± 1.9 vs. 4.4 ± 4.2, P = 0.10). There was no significant correlation between the uptake values (SUVmax and SUVmean) for 18F FPPRGD2 and those for 18F-FDG. Conclusion: The biodistribution of 18F-FPPRGD2 in cancer patients is similar to that of other RGD dimer peptides and it is suitable for clinical use. The lack of significant correlation between 18F-FPPRGD2 and 18F-FDG uptake confirms that the information provided by each PET tracer is different.

Original languageEnglish (US)
Pages (from-to)1850-1858
Number of pages9
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume42
Issue number12
DOIs
StatePublished - Nov 1 2015
Externally publishedYes

Fingerprint

Radiopharmaceuticals
Atlases
Fluorodeoxyglucose F18
Neoplasms
Choroid Plexus
2-fluoropropionyl-PEG3-E(c(RGDyk))2
Salivary Glands
Skeleton
Aspartic Acid
Glycine
Arginine
Pancreas
Thyroid Gland
Urinary Bladder
Spleen
Kidney
Liver
Brain

Keywords

  • F-FPPRGD PET/CT
  • Angiogenesis
  • Atlas
  • PET/CT
  • αβ integrin expression

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Biodistribution of the 18F-FPPRGD2 PET radiopharmaceutical in cancer patients : an atlas of SUV measurements. / Minamimoto, Ryogo; Jamali, Mehran; Barkhodari, Amir; Mosci, Camila; Mittra, Erik; Shen, Bin; Chin, Frederick; Gambhir, Sanjiv Sam; Iagaru, Andrei.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 42, No. 12, 01.11.2015, p. 1850-1858.

Research output: Contribution to journalArticle

Minamimoto, Ryogo ; Jamali, Mehran ; Barkhodari, Amir ; Mosci, Camila ; Mittra, Erik ; Shen, Bin ; Chin, Frederick ; Gambhir, Sanjiv Sam ; Iagaru, Andrei. / Biodistribution of the 18F-FPPRGD2 PET radiopharmaceutical in cancer patients : an atlas of SUV measurements. In: European Journal of Nuclear Medicine and Molecular Imaging. 2015 ; Vol. 42, No. 12. pp. 1850-1858.
@article{6dbf341dbc9445249f04838ffa56291d,
title = "Biodistribution of the 18F-FPPRGD2 PET radiopharmaceutical in cancer patients: an atlas of SUV measurements",
abstract = "Purpose: The aim of this study was to investigate the biodistribution of 2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid (RGD) peptide (PEG3-E[c{RGDyk}]2) (18F-FPPRGD2) in cancer patients and to compare its uptake in malignant lesions with 18F-FDG uptake. Methods: A total of 35 patients (11 men, 24 women, mean age 52.1 ± 10.8 years) were enrolled prospectively and had 18F-FPPRGD2 PET/CT prior to treatment. Maximum standardized uptake values (SUVmax) and mean SUV (SUVmean) were measured in 23 normal tissues in each patient, as well as in known or suspected cancer lesions. Differences between 18F-FPPRGD2 uptake and 18F-FDG uptake were also evaluated in 28 of the 35 patients. Results: Areas of high 18F-FPPRGD2 accumulation (SUVmax range 8.9 – 94.4, SUVmean range 7.1 – 64.4) included the bladder and kidneys. Moderate uptake (SUVmax range 2.1 – 6.3, SUVmean range 1.1 – 4.5) was found in the choroid plexus, salivary glands, thyroid, liver, spleen, pancreas, small bowel and skeleton. Compared with 18F-FDG, 18F-FPPRGD2 showed higher tumor-to-background ratio in brain lesions (13.4 ± 8.5 vs. 1.1 ± 0.5, P < 0.001), but no significant difference in body lesions (3.2 ± 1.9 vs. 4.4 ± 4.2, P = 0.10). There was no significant correlation between the uptake values (SUVmax and SUVmean) for 18F FPPRGD2 and those for 18F-FDG. Conclusion: The biodistribution of 18F-FPPRGD2 in cancer patients is similar to that of other RGD dimer peptides and it is suitable for clinical use. The lack of significant correlation between 18F-FPPRGD2 and 18F-FDG uptake confirms that the information provided by each PET tracer is different.",
keywords = "F-FPPRGD PET/CT, Angiogenesis, Atlas, PET/CT, αβ integrin expression",
author = "Ryogo Minamimoto and Mehran Jamali and Amir Barkhodari and Camila Mosci and Erik Mittra and Bin Shen and Frederick Chin and Gambhir, {Sanjiv Sam} and Andrei Iagaru",
year = "2015",
month = "11",
day = "1",
doi = "10.1007/s00259-015-3096-4",
language = "English (US)",
volume = "42",
pages = "1850--1858",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Biodistribution of the 18F-FPPRGD2 PET radiopharmaceutical in cancer patients

T2 - an atlas of SUV measurements

AU - Minamimoto, Ryogo

AU - Jamali, Mehran

AU - Barkhodari, Amir

AU - Mosci, Camila

AU - Mittra, Erik

AU - Shen, Bin

AU - Chin, Frederick

AU - Gambhir, Sanjiv Sam

AU - Iagaru, Andrei

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Purpose: The aim of this study was to investigate the biodistribution of 2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid (RGD) peptide (PEG3-E[c{RGDyk}]2) (18F-FPPRGD2) in cancer patients and to compare its uptake in malignant lesions with 18F-FDG uptake. Methods: A total of 35 patients (11 men, 24 women, mean age 52.1 ± 10.8 years) were enrolled prospectively and had 18F-FPPRGD2 PET/CT prior to treatment. Maximum standardized uptake values (SUVmax) and mean SUV (SUVmean) were measured in 23 normal tissues in each patient, as well as in known or suspected cancer lesions. Differences between 18F-FPPRGD2 uptake and 18F-FDG uptake were also evaluated in 28 of the 35 patients. Results: Areas of high 18F-FPPRGD2 accumulation (SUVmax range 8.9 – 94.4, SUVmean range 7.1 – 64.4) included the bladder and kidneys. Moderate uptake (SUVmax range 2.1 – 6.3, SUVmean range 1.1 – 4.5) was found in the choroid plexus, salivary glands, thyroid, liver, spleen, pancreas, small bowel and skeleton. Compared with 18F-FDG, 18F-FPPRGD2 showed higher tumor-to-background ratio in brain lesions (13.4 ± 8.5 vs. 1.1 ± 0.5, P < 0.001), but no significant difference in body lesions (3.2 ± 1.9 vs. 4.4 ± 4.2, P = 0.10). There was no significant correlation between the uptake values (SUVmax and SUVmean) for 18F FPPRGD2 and those for 18F-FDG. Conclusion: The biodistribution of 18F-FPPRGD2 in cancer patients is similar to that of other RGD dimer peptides and it is suitable for clinical use. The lack of significant correlation between 18F-FPPRGD2 and 18F-FDG uptake confirms that the information provided by each PET tracer is different.

AB - Purpose: The aim of this study was to investigate the biodistribution of 2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid (RGD) peptide (PEG3-E[c{RGDyk}]2) (18F-FPPRGD2) in cancer patients and to compare its uptake in malignant lesions with 18F-FDG uptake. Methods: A total of 35 patients (11 men, 24 women, mean age 52.1 ± 10.8 years) were enrolled prospectively and had 18F-FPPRGD2 PET/CT prior to treatment. Maximum standardized uptake values (SUVmax) and mean SUV (SUVmean) were measured in 23 normal tissues in each patient, as well as in known or suspected cancer lesions. Differences between 18F-FPPRGD2 uptake and 18F-FDG uptake were also evaluated in 28 of the 35 patients. Results: Areas of high 18F-FPPRGD2 accumulation (SUVmax range 8.9 – 94.4, SUVmean range 7.1 – 64.4) included the bladder and kidneys. Moderate uptake (SUVmax range 2.1 – 6.3, SUVmean range 1.1 – 4.5) was found in the choroid plexus, salivary glands, thyroid, liver, spleen, pancreas, small bowel and skeleton. Compared with 18F-FDG, 18F-FPPRGD2 showed higher tumor-to-background ratio in brain lesions (13.4 ± 8.5 vs. 1.1 ± 0.5, P < 0.001), but no significant difference in body lesions (3.2 ± 1.9 vs. 4.4 ± 4.2, P = 0.10). There was no significant correlation between the uptake values (SUVmax and SUVmean) for 18F FPPRGD2 and those for 18F-FDG. Conclusion: The biodistribution of 18F-FPPRGD2 in cancer patients is similar to that of other RGD dimer peptides and it is suitable for clinical use. The lack of significant correlation between 18F-FPPRGD2 and 18F-FDG uptake confirms that the information provided by each PET tracer is different.

KW - F-FPPRGD PET/CT

KW - Angiogenesis

KW - Atlas

KW - PET/CT

KW - αβ integrin expression

UR - http://www.scopus.com/inward/record.url?scp=84942987699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942987699&partnerID=8YFLogxK

U2 - 10.1007/s00259-015-3096-4

DO - 10.1007/s00259-015-3096-4

M3 - Article

C2 - 26062933

AN - SCOPUS:84942987699

VL - 42

SP - 1850

EP - 1858

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 12

ER -